Traders should monitor post-offering price action for TSHA given the 13.6% discount to prior close — anticipate near-term selling pressure as the market absorbs ~32.5M new shares. The 60-day lockup on insiders/executives limits insider selling, but underwriters may release shares early. Key catalysts: REVEAL pivotal trial 6-month interim analysis (topline data expected H1 2027) and FDA Type C meeting follow-up. Pro forma cash of ~$464M removes near-term financing risk and funds BLA preparation.
Price Chart
Executive Summary
Taysha Gene Therapies is raising approximately $187.4 million ($215.6 million if underwriters' option is exercised) through the sale of 32.5M shares of common stock and pre-funded warrants at $6.00 per share, representing a 13.6% discount to the $6.94 prior closing price. Net proceeds combined with existing $276.6M cash will fund TSHA-102 BLA preparation/commercial launch and pipeline development, extending runway into H2 2028. The offering creates immediate 79% dilution ($4.75/share) for new investors.
Key Facts
- Offering of 32,500,001 shares of common stock at $6.00/share, a 13.6% discount to the prior close of $6.94
- Pre-funded warrants for up to 833,333 additional shares at $5.999 per warrant (exercise price $0.001)
- Net proceeds estimated at $187.4M (or $215.6M with underwriter option exercise)
- Immediate dilution of $4.75 per share for new investors (79% of offering price)
- Post-offering shares outstanding increase to 319,776,886 from 287,276,885 (11.3% increase)
- Cash and equivalents of $276.6M as of March 31, 2026; pro forma cash ~$464M
- Underwriters have 30-day option to purchase 5,000,000 additional shares
Financial Impact
Gross proceeds of $200M; net proceeds ~$187.4M after underwriting discounts and expenses. Immediate dilution of $4.75/share (79%) to new investors at $6.00 offering price. Post-offering cash runway extended to H2 2028.
Risk Factors
- Significant immediate dilution (79%) may pressure stock price
- Pre-funded warrant exercises could add further dilution
- Clinical-stage biotech with no approved products — regulatory/clinical risk remains high
- Underwriters may release lock-up shares early, increasing supply
- Cash burn rate for clinical/CMC activities could accelerate if trials expand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-282846 |
| Document: d95601dexfilingfees.htm | 0001193125-26-282846 |
| Document: 0001193125-26-282846-index-headers.html | 0001193125-26-282846 |
| Document: 0001193125-26-282846-index.html | 0001193125-26-282846 |
| Document: 0001193125-26-282846.txt | 0001193125-26-282846 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Press Release | $6.41 $5.16 | ▼ −19.44% | ▼ −17.54% | $4.63 (−27.71%) |
Jun 25, 2026 14w ago | 8-K | $6.34 $5.83 | ▼ −8.04% | ▼ −9.30% | $4.63 (−26.97%) |
Jun 25, 2026 14w ago | 424B5 | $6.34 $5.83 | ▲ +8.04% | ▲ +9.30% | $4.63 (+26.97%) |
Jun 25, 2026 14w ago | Press Release | $6.21 $5.83 | ▲ +6.12% | ▲ +6.65% | $4.63 (+25.44%) |
Jun 5, 2026 17w ago | Press Release | $5.50 $6.38 | ▲ +16.00% | ▲ +14.14% | $4.63 (−15.82%) |
May 6, 2026 21w ago | 8-K | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.63 (−33.67%) |
May 6, 2026 21w ago | Press Release | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.63 (−33.67%) |
Apr 29, 2026 22w ago | Press Release | $6.27 $5.75 | ▼ −8.29% | ▼ −13.75% | $4.63 (−26.16%) |
Apr 27, 2026 22w ago | Press Release | $6.30 $5.59 | ▼ −11.27% | ▼ −16.74% | $4.63 (−26.51%) |
Apr 22, 2026 23w ago | DEFA14A | $6.72 $5.19 | ▼ −22.84% | ▼ −26.01% | $4.63 (−31.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access